Simcere Pharmaceutical Group Limited (the “Group”), which entered into an option to license agreement with a subsidiary of AbbVie Inc. (“AbbVie”) for an investigational new drug candidate known as SIM0500, has recently received a US$40 million payment from AbbVie. This payment follows the previously disclosed upfront amount and signifies ongoing progress in the collaboration between the two companies.

The agreement outlines a total potential milestone payment of up to US$1.055 billion and also includes tiered royalty arrangements on net sales. According to available information, SIM0500 is a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3, designed to harness T-cell cytotoxicity against multiple myeloma cells.

Simcere Pharmaceutical Group Limited focuses primarily on research and development in the therapeutic areas of neuroscience, oncology, autoimmune, and anti-infection. The Group’s forward-looking platform aims to fulfill significant clinical needs and leverages both internal R&D capabilities and collaborations with multiple innovative organizations and research institutes.